Abstract: The present invention is directed to novel chewable or dissolvable nutritional supplements for improving the absorption of folic acid in humans and other animals and methods of using said supplements. The nutritional supplements contain folic acid and non-toxic acid neutralizing alkaline compounds in chewable or dissolvable forms.

Abstract: The present disclosure relates to novel nutritional compositions containing linoleic acid and/or linolenic acid which optimize child neurological development and provide improved nutritional support for women prior to and during lactation. The nutritional compositions are intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.

Abstract: Multi-vitamin and mineral supplements for administration to a pregnant woman during her first, second, and third trimesters of pregnancy comprising specific regimens of a pharmaceutically acceptable calcium compound, vitamin D, folic acid, vitamin B12, vitamin B6, and vitamin B1. The prenatal supplements are specifically tailored to maximize fetal development and maternal health during each trimester of pregnancy.

Abstract: The present disclosure is directed to novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using same. The compositions provide improved relief from nausea and/or vomiting. The compositions are particularly useful for pregnant women.

Abstract: Multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women, which comprise specific regimens of critical nutritional agents. The supplements are specifically tailored to meet nutritional requirements and maintain a woman's health during each stage of life.

Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.

Abstract: A substantially tasteless liquid phramaceutical delivery system containing an active material and a high osmolarity aqueous system comprising (i) water; (ii) about 20% to about 45% by weight sugar derivative; (iii) about 10% to about 15% by weight hydrogenated maltose syrup; and (iv) about 0% to about 35% by weight polyhydroxy alcohol.

Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.

Abstract: A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms is disclosed.

Abstract: A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms is disclosed.

Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about l% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.

Abstract: A solid or semi-solid bioadherent, orally ingestible drug delivery system containing a water-in-oil system having at least two phases, one phase comprises from about 25% to about 75% by volume of an internal hydrophilic phase and the other phase comprises from about 25% to about 75% by volume of an external hydrophobic phase and wherein the external hydrophobic phase is comprised of three components, a) an emulsifier, b) a glyceride ester and c) a wax material.

Abstract: A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within the range of about 50.degree. C. and about 200.degree. C.; and (ii) a regional hydrophobic polymer material and method for making the same.

Abstract: Multi-vitamin and mineral supplements for administration to a pregnant woman during her first, second, and third trimesters of pregnancy comprising specific regimens of a pharmaceutically acceptable calcium compound, vitamin D, folic acid, vitamin B.sub.12, vitamin B.sub.6, and vitamin B.sub.1. The prenatal supplements are specifically tailored to maximize fetal development and maternal health during each trimester of pregnancy.

Abstract: A method is disclosed for preparing pharmaceutical and other matrix systems that comprises solidifying a matrix composition dissolved or dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix components being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a usable matrix.

Abstract: A method is disclosed for preparing pharmaceutical and other matrix systems that comprises solidifying a matrix composition dissolved or dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix components being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a usable matrix.

Abstract: A method is disclosed for preparing pharmaceutical and other matrix systems that comprises solidifying a matrix composition dissolved or dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix components being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a usable matrix.

Abstract: Shock absorbing devices utilize rheopexic fluid contained in a deformable sealed chamber which is subjected to external shock forces. Upon application of the shock forces to the deformable sealed chamber, the rheopexic fluid filled therein is exerted with shear stress which causes the rheopexic fluid to increase its consistency and shock absorbent characteristics as a function of increasing shear stresses applied thereto. Additionally, when used in an application wherein the device is placed against a body part of a user, the rheopexic material "molds" itself to the body portion of the user. When left at rest, the rheopexic material returns to its initial fluid, low-consistency state.